Phone (336) 292-1510
Fax (336) 292-0679

Receive our eNewsletter

  Home  
  Our Team  
  Patient Info  
  Services  

News for Healthier Living

Adding Immune Checkpoint Inhibitor to Standard Chemotherapy Regimen Improves Outcomes in Stage 3 Colon Cancer, Study Finds

Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon cancer that is deficient in DNA mismatch repair (dMMR), Dana-Farber Cancer Institute investigator Dr. Jeffrey Meyerhardt and his colleagues report at the 2025 American Society of Clinical Oncology (ASCO) meeting.

June 1, 2025


July 5 2025

July 4 2025

July 3 2025

July 2 2025

July 1 2025

June 30 2025

June 29 2025

June 28 2025

June 27 2025

June 26 2025

June 25 2025

June 24 2025

June 23 2025

June 22 2025

June 21 2025